MarketCap
Facebook
X
TelegramQuarterly report 2025-Q1
added 05-01-2025
Blueprint Medicines Corporation Net Income 2011-2026 | BPMC
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Blueprint Medicines Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -67.1 M | -507 M | -558 M | -644 M | 314 M | -348 M | -237 M | -148 M | -72.5 M | -52.8 M | -40.3 M | -20.9 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 314 M | -644 M | -198 M |
Quarterly Net Income Blueprint Medicines Corporation
| 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 496 K | - | -56.3 M | -50 M | 89.1 M | - | -134 M | -133 M | -130 M | - | -133 M | -160 M | -106 M | - | -117 M | -108 M | -99.7 M | - | 634 M | -123 M | -111 M | -66.3 M | -94.3 M | -99.7 M | -87.4 M | -80.3 M | -72.7 M | -27 M | -56.5 M | -49 M | -37.7 M | -33.4 M | -28 M | -21.3 M | -16.8 M | -18.9 M | -15.5 M | -15.6 M | -12.6 M | -13 M | -11.6 M | -14.5 M | -10.5 M | -8.29 M | -7.03 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 634 M | -160 M | -40.9 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-514 M | - | 2.43 % | $ 254 M |  Germany |
 |
Graybug Vision
GRAY
|
-29.6 M | - | -11.23 % | $ 9.65 M |  USA |
 |
AbCellera Biologics
ABCL
|
-146 M | $ 3.64 | -1.89 % | $ 1.09 B |  Canada |
 |
ADMA Biologics
ADMA
|
147 M | $ 16.45 | 0.43 % | $ 3.92 B | USA |
 |
I-Mab
IMAB
|
-1.47 B | - | - | $ 866 M |  China |
 |
ANI Pharmaceuticals
ANIP
|
-18.5 M | $ 76.75 | 0.85 % | $ 1.48 B | USA |
 |
Apellis Pharmaceuticals
APLS
|
22.4 M | $ 19.93 | -1.14 % | $ 2.51 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
603 M | - | - | $ 40.3 B | USA |
 |
Acer Therapeutics
ACER
|
-26.2 M | - | 2.71 % | $ 14 M | USA |
 |
Biophytis SA
BPTS
|
-31.2 M | - | -13.47 % | $ 169 M |  France |
 |
Ampio Pharmaceuticals
AMPE
|
-8.63 M | - | -11.43 % | $ 502 K | USA |
 |
Aptorum Group Limited
APM
|
-4.27 M | $ 0.83 | 4.23 % | $ 4.53 M | China |
 |
Athersys
ATHX
|
-87 M | - | 3.77 % | $ 22.4 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.09 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-5.46 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
-53.3 M | - | - | $ 521 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-11.6 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
84.9 M | - | -4.8 % | $ 255 M | USA |
 |
Burford Capital Limited
BUR
|
172 M | $ 8.4 | -1.81 % | $ 1.39 B | Britain |
 |
Axsome Therapeutics
AXSM
|
-183 M | $ 163.82 | -0.14 % | $ 8.15 B | USA |
 |
Adverum Biotechnologies
ADVM
|
-131 M | - | - | $ 86.2 M | USA |
 |
BridgeBio Pharma
BBIO
|
-733 M | $ 66.98 | 3.8 % | $ 12.8 B | USA |
 |
CymaBay Therapeutics
CBAY
|
-105 M | - | - | $ 3.45 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
72.9 M | - | - | - |  Russia |
 |
Avid Bioservices
CDMO
|
-141 M | - | - | $ 789 M | USA |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
-56.2 M | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
-20 M | - | -16.75 % | $ 25.8 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-57.8 M | - | - | $ 2.17 B | USA |
 |
BioLineRx Ltd.
BLRX
|
-27.1 M | $ 2.88 | 2.51 % | $ 908 M |  Israel |
 |
Clovis Oncology
CLVS
|
-265 M | - | -7.23 % | $ 13 M | USA |
 |
Acorda Therapeutics
ACOR
|
-253 M | - | -24.86 % | $ 820 K | USA |
 |
BioMarin Pharmaceutical
BMRN
|
349 M | $ 60.75 | 3.79 % | $ 11.7 B | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-61.4 M | - | - | $ 231 M | USA |
 |
Acasti Pharma
ACST
|
-9.57 M | - | 4.01 % | $ 150 M | Canada |
 |
CTI BioPharma Corp.
CTIC
|
-93 M | - | - | $ 1.2 B | USA |
 |
CohBar
CWBR
|
-12.2 M | - | -15.44 % | $ 2.2 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
-11.2 M | - | -5.98 % | $ 34.1 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-11.2 M | - | -4.36 % | $ 27 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-195 M | - | - | $ 2.18 B | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
-8.37 M | - | 5.93 % | $ 314 M | Canada |
 |
Cabaletta Bio
CABA
|
-67.7 M | $ 3.41 | 4.77 % | $ 3.98 M | USA |
 |
Capricor Therapeutics
CAPR
|
-22.3 M | $ 25.71 | -0.5 % | $ 688 M | USA |
 |
AgeX Therapeutics
AGE
|
-14.8 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-155 M | - | - | $ 1.01 B | USA |
 |
Codexis
CDXS
|
-65.3 M | $ 1.1 | 12.24 % | $ 80.7 M | USA |
 |
Certara
CERT
|
-1.6 M | $ 7.33 | 1.24 % | $ 1.18 B | USA |
 |
Entasis Therapeutics Holdings
ETTX
|
-47.1 M | - | - | $ 105 M | USA |
 |
Evofem Biosciences
EVFM
|
53 M | - | 7.55 % | $ 38.1 M | USA |